Characterization of SARS‐CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence‐based assay
暂无分享,去创建一个
[1] Jiahai Shi,et al. Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme , 2004, Journal of Biological Chemistry.
[2] J. Hsu,et al. Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate , 2004, Biochemical and Biophysical Research Communications.
[3] A. Velázquez‐Campoy,et al. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. , 2004, Biochemistry.
[4] Mayuko Takeda-Shitaka,et al. Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design. , 2004, Chemical & pharmaceutical bulletin.
[5] Y. Liu,et al. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. , 2004, Biochemistry.
[6] Xue Wu Zhang,et al. Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design , 2004, Bioorganic & Medicinal Chemistry.
[7] Andreas Koeller,et al. Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. , 2004, Journal of medicinal chemistry.
[8] Luhua Lai,et al. Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase , 2004, Journal of Biological Chemistry.
[9] G. Gao,et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[10] Scott D. Kahn,et al. Assessment of putative protein targets derived from the SARS genome , 2003, FEBS Letters.
[11] Kaixian Chen,et al. Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus , 2003, Protein Expression and Purification.
[12] Ram Samudrala,et al. Identifying inhibitors of the SARS coronavirus proteinase , 2003, Bioorganic & Medicinal Chemistry Letters.
[13] Rolf Hilgenfeld,et al. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.
[14] Cheng Luo,et al. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. , 2003, Acta pharmacologica Sinica.
[15] Christian Drosten,et al. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.
[16] Obi L. Griffith,et al. The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.
[17] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[18] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[19] Y. Guan,et al. Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.
[20] D. Norbeck,et al. Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides. , 1999, Archives of biochemistry and biophysics.
[21] Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. , 1996, Journal of medicinal chemistry.
[22] B. Dunn,et al. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. , 1995, Analytical biochemistry.
[23] C. Dolea,et al. World Health Organization , 1949, International Organization.